Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith J Simons

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
Biopharmaceutics & Drug Disposition|September 30, 2006
Epinephrine for the treatment of anaphylaxis: do all 40 mg sublingual epinephrine tablet formulations with similar in vitro characteristics have the same bioavailability?Mutasem M Rawas-Qalaji, F Estelle R Simons, Keith J Simons
The Journal of Allergy and Clinical Immunology|February 8, 2006
Sublingual epinephrine tablets versus intramuscular injection of epinephrine: dose equivalence for potential treatment of anaphylaxisMutasem M Rawas-Qalaji, F Estelle R Simons, Keith J Simons
AAPS Pharmscitech|April 28, 2011
Dissolution testing of sublingual tablets: a novel in vitro methodOusama Rachid, Mutasem Rawas-Qalaji, F Estelle R Simons, et al.
AAPS Pharmscitech|March 31, 2010
An electronic tongue: evaluation of the masking efficacy of sweetening and/or flavoring agents on the bitter taste of epinephrineOusama Rachid, F Estelle R Simons, Mutasem Rawas-Qalaji, et al.
The Journal of Allergy and Clinical Immunology|January 19, 2002
EpiPen Jr versus EpiPen in young children weighing 15 to 30 kg at risk for anaphylaxisF Estelle R Simons, Xiaochen Gu, Norman A Silver, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|June 12, 2012
Rapidly-disintegrating sublingual tablets of epinephrine: role of non-medicinal ingredients in formulation developmentOusama Rachid, Mutasem Rawas-Qalaji, F Estelle R Simons, et al.
Drug Development and Industrial Pharmacy|December 15, 2004
Evaluation and comparison of five matrix excipients for the controlled release of acrivastine and pseudoephedrineXiaochen Gu, Daryl J Fediuk, F Estelle R Simons, et al.
The Journal of Allergy and Clinical Immunology|November 6, 2002
Clinical pharmacology of H1-antihistamines in the skinF Estelle R Simons, Norman A Silver, Xiaochen Gu, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|June 30, 2009
Long-term stability of epinephrine dispensed in unsealed syringes for the first-aid treatment of anaphylaxisMutasem Rawas-Qalaji, F Estelle R Simons, David Collins, et al.
AAPS Pharmsci|June 17, 2004
Hydroxyzine from topical phospholipid liposomal formulations: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit modelAbeer A W Elzainy, Xiaochen Gu, F Estelle R Simons, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Biopharmaceutics & Drug Disposition|September 30, 2006
Epinephrine for the treatment of anaphylaxis: do all 40 mg sublingual epinephrine tablet formulations with similar in vitro characteristics have the same bioavailability?Mutasem M Rawas-Qalaji, F Estelle R Simons, Keith J Simons
The Journal of Allergy and Clinical Immunology|February 8, 2006
Sublingual epinephrine tablets versus intramuscular injection of epinephrine: dose equivalence for potential treatment of anaphylaxisMutasem M Rawas-Qalaji, F Estelle R Simons, Keith J Simons
AAPS Pharmscitech|April 28, 2011
Dissolution testing of sublingual tablets: a novel in vitro methodOusama Rachid, Mutasem Rawas-Qalaji, F Estelle R Simons, et al.
AAPS Pharmscitech|March 31, 2010
An electronic tongue: evaluation of the masking efficacy of sweetening and/or flavoring agents on the bitter taste of epinephrineOusama Rachid, F Estelle R Simons, Mutasem Rawas-Qalaji, et al.
The Journal of Allergy and Clinical Immunology|January 19, 2002
EpiPen Jr versus EpiPen in young children weighing 15 to 30 kg at risk for anaphylaxisF Estelle R Simons, Xiaochen Gu, Norman A Silver, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|June 12, 2012
Rapidly-disintegrating sublingual tablets of epinephrine: role of non-medicinal ingredients in formulation developmentOusama Rachid, Mutasem Rawas-Qalaji, F Estelle R Simons, et al.
Drug Development and Industrial Pharmacy|December 15, 2004
Evaluation and comparison of five matrix excipients for the controlled release of acrivastine and pseudoephedrineXiaochen Gu, Daryl J Fediuk, F Estelle R Simons, et al.
The Journal of Allergy and Clinical Immunology|November 6, 2002
Clinical pharmacology of H1-antihistamines in the skinF Estelle R Simons, Norman A Silver, Xiaochen Gu, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|June 30, 2009
Long-term stability of epinephrine dispensed in unsealed syringes for the first-aid treatment of anaphylaxisMutasem Rawas-Qalaji, F Estelle R Simons, David Collins, et al.
AAPS Pharmsci|June 17, 2004
Hydroxyzine from topical phospholipid liposomal formulations: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit modelAbeer A W Elzainy, Xiaochen Gu, F Estelle R Simons, et al.
Pageof 4